Akrocell Biosciences

Established by Jeollanam-do Province, Jeonnam Bio Foundation is a public

institution dedicated to fostering the regional biopharmaceutical industry

— supporting emerging biotech companies through incubation,

infrastructure, and commercialization resources.

JBF operates GMP-certified biopharmaceutical manufacturing facilities,

providing CDMO services that enable early-stage companies to advance

from pilot-scale to commercial-scale production.

Akrocell and JBF formalized a strategic investment partnership in April 2025

— collaborating to build the manufacturing foundation for species-specific

exosome therapeutics together.

Jeonnam National University Veterinary Medical Teaching Hospital is one of

Korea's leading academic veterinary medical centers, providing advanced

diagnostics, specialized clinical care, and research capabilities across

companion and farm animals.

The hospital operates dedicated programs in stem cell therapy, immune

therapy, and artificial kidney dialysis — representing the frontier of

veterinary regenerative medicine in Korea.

In August 2025, Akrocell and the hospital formalized a research collaboration

MOU, establishing a partnership spanning basic and applied research,

clinical trial design and execution, and technology commercialization

for the LE-AD therapeutic series.

Established by Jeollanam-do Province, Jeonnam Bio Foundation is a public institution dedicated to fostering the regional biopharmaceutical industry — supporting emerging biotech companies through incubation, infrastructure, and commercialization resources.

JBF operates GMP-certified biopharmaceutical manufacturing facilities, providing CDMO services that enable early-stage companies to advance from pilot-scale to commercial-scale production.

Akrocell and JBF formalized a strategic investment partnership in April 2025 — collaborating to build the manufacturing foundation for species-specific exosome therapeutics together.

Jeonnam National University Veterinary Medical Teaching Hospital is one of Korea's leading academic veterinary medical centers, providing advanced diagnostics, specialized clinical care, and research capabilities across companion and farm animals.

The hospital operates dedicated programs in stem cell therapy, immune therapy, and artificial kidney dialysis — representing the frontier of veterinary regenerative medicine in Korea.

In August 2025, Akrocell and the hospital formalized a research collaboration MOU, establishing a partnership spanning basic and applied research, clinical trial design and execution, and technology commercialization for the LE-AD therapeutic series.